Background/Aim: Few clinical trials are available for advanced biliary tract carcinoma (BTC). We conducted this randomized phase II clinical trial to explore efficacy and safety of 5-fluorouracil/leucovorin (5-FU/LV-de Gramont) or the same regimen plus oxaliplatin (Folfox 4) as first-line treatment of advanced BTC. Patients and Methods: Primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS), response and toxicity. Results: A total of 48 patients were enrolled, 23 in de Gramont arm and 25 in the Folfox arm. Disease control rate was 56.5% for de Gramont vs. 72% for Folfox. RR was 21.7% for de Gramont arm and 28% for Folfox arm (p=0.12). PFS was in favor of Folfox (5.2 vs. 2.8 months; p=0.031). OS was 7.5 and 13.0 months for de Gramont and Folfox arm respectively (p=0.0010). Toxicity was generally mild in both arms. Conclusion: Folfox 4 could be considered a valid option as first-line treatment of BTC due to its efficacy and tolerability.

Schinzari, G., Rossi, E., Mambella, G., Strippoli, A., Cangiano, R., Mutignani, M., Basso, M., Cassano, A., Barone, C. A., First-line treatment of advanced biliary ducts carcinoma: A randomized phase II study evaluating 5-FU/LV Plus oxaliplatin (Folfox 4) versus 5-FU/LV (de gramont regimen), <<ANTICANCER RESEARCH>>, 2017; 37 (9): 5193-5197. [doi:10.21873/anticanres.11942] [http://hdl.handle.net/10807/122909]

First-line treatment of advanced biliary ducts carcinoma: A randomized phase II study evaluating 5-FU/LV Plus oxaliplatin (Folfox 4) versus 5-FU/LV (de gramont regimen)

Schinzari, Giovanni
Primo
;
Rossi, Ernesto;Strippoli, Antonia;Cangiano, Rodolfo;Mutignani, Massimiliano;Basso, Michele;Cassano, Alessandra;Barone, Carlo Antonio
2017

Abstract

Background/Aim: Few clinical trials are available for advanced biliary tract carcinoma (BTC). We conducted this randomized phase II clinical trial to explore efficacy and safety of 5-fluorouracil/leucovorin (5-FU/LV-de Gramont) or the same regimen plus oxaliplatin (Folfox 4) as first-line treatment of advanced BTC. Patients and Methods: Primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS), response and toxicity. Results: A total of 48 patients were enrolled, 23 in de Gramont arm and 25 in the Folfox arm. Disease control rate was 56.5% for de Gramont vs. 72% for Folfox. RR was 21.7% for de Gramont arm and 28% for Folfox arm (p=0.12). PFS was in favor of Folfox (5.2 vs. 2.8 months; p=0.031). OS was 7.5 and 13.0 months for de Gramont and Folfox arm respectively (p=0.0010). Toxicity was generally mild in both arms. Conclusion: Folfox 4 could be considered a valid option as first-line treatment of BTC due to its efficacy and tolerability.
2017
Inglese
Schinzari, G., Rossi, E., Mambella, G., Strippoli, A., Cangiano, R., Mutignani, M., Basso, M., Cassano, A., Barone, C. A., First-line treatment of advanced biliary ducts carcinoma: A randomized phase II study evaluating 5-FU/LV Plus oxaliplatin (Folfox 4) versus 5-FU/LV (de gramont regimen), <<ANTICANCER RESEARCH>>, 2017; 37 (9): 5193-5197. [doi:10.21873/anticanres.11942] [http://hdl.handle.net/10807/122909]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/122909
Citazioni
  • ???jsp.display-item.citation.pmc??? 7
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 14
social impact